Ligand Pharmaceuticals (LGND) Interest Coverage Ratio (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Interest Coverage Ratio of 1.17 for Q1 2026, down 99.81% sequentially from 629.23 in Q4 2025, and up 102.79% YoY from 0.57 in Q1 2025.
Ligand Pharmaceuticals (LGND) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Interest Coverage Ratio for 17 years, with the latest figure at 1.17 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 102.79% year-over-year to 1.17 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.35 (up 158.04% YoY) and the FY2025 annual result came in at 1.3, up 509.83% from the prior year.
- Interest Coverage Ratio eased to 1.17 in Q1 2026 per LGND's latest filing, from 629.23 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 3078.0 in Q3 2023 and troughed at 83.75 in Q4 2022.
- A 5-year average of 222.94 and a median of 3.69 in 2025 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio sank 3196.71% in 2024, then soared 18218.77% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 83.75 in 2022, then jumped by 96.39% to 3.02 in 2023, then decreased by 15.0% to 3.47 in 2024, then jumped by 18218.77% to 629.23 in 2025, then tumbled by 99.81% to 1.17 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1.17, 629.23, and 3.69 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 0.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.26 |
| Mar 31, 2026 | 1.17 |
| Dec 31, 2025 | 629.23 |
| Sep 30, 2025 | 3.69 |
| Jun 30, 2025 | 81.19 |
| Mar 31, 2025 | -41.77 |
| Dec 31, 2024 | -3.47 |
| Sep 30, 2024 | 4.24 |
| Jun 30, 2024 | -15.06 |
| Mar 31, 2024 | 21.19 |
| Dec 31, 2023 | -3.02 |
| Sep 30, 2023 | 3,078.00 |
| Jun 30, 2023 | -0.46 |
| Mar 31, 2023 | 59.19 |
| Dec 31, 2022 | -83.75 |
| Sep 30, 2022 | 37.17 |
| Jun 30, 2022 | 19.78 |
| Mar 31, 2022 | 2.70 |
| Dec 31, 2021 | 8.44 |
| Sep 30, 2021 | 3.54 |